Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Zacks Investment Research - ATE upgareded to $28/share

<< Previous

Bullboard Posts

Next >>

Post by Alex1967on Dec 07, 2020 5:25pm

485 Views

Post# 32054418

Zacks Investment Research - ATE upgareded to $28/share

Antibe continues to execute on its strategy as it moves otenaproxesul toward initiation ofa global Phase 3 program. We anticipate an IND filing and an ‘End of Phase 2’meeting to occur during the first half of 2021 such that the first Phase 3 clinical trial can initiate by the end of the second quarter of 2021, withsubsequent trials initiating over the subsequent months. We are looking forward to continued updates as the company meets with regulatory authorities in preparation for the Phase 3 program. We have adjusted our model to account for the recent 1:10 share consolidation and our valuation is CAD$28.00 per share

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale